logo
AAA warns of increased teen driving risks during summer

AAA warns of increased teen driving risks during summer

Yahoo27-05-2025

ORCHARD PARK, N.Y. (WIVB) — Memorial Day marked the beginning of the '100 Deadliest Days,' a stretch of summer where fatal crashes involving teen drivers rise significantly. AAA is urging both parents and teens to take extra precautions on the road.
'This time period from Memorial Day to Labor Day is when fatal teen crashes increase dramatically,' said Elizabeth Carey, director of public relations for AAA. 'The latest numbers from 2023 show that 863 people were killed during that summer. That's about eight people per day, compared to seven during the rest of the year. We want to educate people, share information and curb this trend.'
AAA officials say some of the biggest distractions for teen drivers are phones and passengers.
'One of the bigger distractions for a new driver, believe it or not, is other people in the vehicle with them,' said Michael Formanowicz, AAA's manager of driver training. 'The phone is a distraction because if they're texting or talking, their eyes may not be on the road, and they're not thinking about the process of driving. The same thing happens if they're talking to passengers.'
Teen driver Erynn Ras said she knows how tempting it can be to check her phone, especially during the summer months.
'My phone is probably my biggest distraction,' Ras said. 'Hearing the notification or seeing it on CarPlay definitely makes me want to grab it, especially in the summer when we're not in school and there's a lot going on during the day.'
To resist the urge, Ras keeps her phone in the middle console or glove compartment while driving, something AAA encourages, especially among parents, who often serve as role models for young drivers.
'We always encourage parents to exhibit the best driving skills they possibly can,' Formanowicz said. 'That means staying undistracted, coming to complete stops, using head checks when merging, those behaviors are important.'
AAA recommends families have early and ongoing conversations with their teens about safe driving habits throughout the summer.
Gwyn Napier is a reporter who joined the News 4 team in 2025. See more of her work by clicking here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is It Worth Investing in Sensus Healthcare (SRTS) Based on Wall Street's Bullish Views?
Is It Worth Investing in Sensus Healthcare (SRTS) Based on Wall Street's Bullish Views?

Yahoo

time37 minutes ago

  • Yahoo

Is It Worth Investing in Sensus Healthcare (SRTS) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Sensus Healthcare, Inc. (SRTS). Sensus Healthcare currently has an average brokerage recommendation (ABR) of 1.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by four brokerage firms. An ABR of 1.00 indicates Strong Buy. Of the four recommendations that derive the current ABR, four are Strong Buy, representing 100% of all recommendations. Check price target & stock forecast for Sensus Healthcare here>>>The ABR suggests buying Sensus Healthcare, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. In terms of earnings estimate revisions for Sensus Healthcare, the Zacks Consensus Estimate for the current year has declined 61.4% over the past month to $0.11. Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for Sensus Healthcare. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, it could be wise to take the Buy-equivalent ABR for Sensus Healthcare with a grain of salt. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sensus Healthcare, Inc. (SRTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Yahoo

timean hour ago

  • Yahoo

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company's lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Phase 2 prexigebersen data shows potential for FDA approval in AML treatment. BP1001-A trial shows early signs of efficacy in advanced solid tumors. Advancing pipeline backed by strategic R&D and a robust patent portfolio. Click image above to view full announcement. About StonegateStonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners (214) 987-4121 info@ Source: Stonegate, Inc. To view the source version of this press release, please visit

SI-BONE to Truist Securities MedTech Conference on June 17, 2025
SI-BONE to Truist Securities MedTech Conference on June 17, 2025

Yahoo

timean hour ago

  • Yahoo

SI-BONE to Truist Securities MedTech Conference on June 17, 2025

SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: Truist Securities MedTech Conference. Live audio of the webcast will be available on the 'Investors' section of the company's website at: The webcast will be archived and available for replay for at least 90 days after the event. About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,500 physicians in performing a total of over 120,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies with over 160 peer reviewed publications including two randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma. For additional information on the company or the products, including risks and benefits, please visit SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved. Investor Contact: Saqib Iqbal, investors@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store